Last reviewed · How we verify
13-C-Methacetin — Competitive Intelligence Brief
phase 3
Diagnostic tracer / Stable isotope breath test
Diagnostics / Hepatology
Small molecule
Live · refreshed every 30 min
Target snapshot
13-C-Methacetin (13-C-Methacetin) — Humedics GmbH. 13-C-Methacetin is a stable isotope-labeled tracer used to assess hepatic metabolic function and liver synthetic capacity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 13-C-Methacetin TARGET | 13-C-Methacetin | Humedics GmbH | phase 3 | Diagnostic tracer / Stable isotope breath test |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Diagnostic tracer / Stable isotope breath test class)
- Humedics GmbH · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 13-C-Methacetin CI watch — RSS
- 13-C-Methacetin CI watch — Atom
- 13-C-Methacetin CI watch — JSON
- 13-C-Methacetin alone — RSS
- Whole Diagnostic tracer / Stable isotope breath test class — RSS
Cite this brief
Drug Landscape (2026). 13-C-Methacetin — Competitive Intelligence Brief. https://druglandscape.com/ci/13-c-methacetin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing